JP2010502210A - 遺伝子マーカーを使用する癌幹細胞の同定 - Google Patents
遺伝子マーカーを使用する癌幹細胞の同定 Download PDFInfo
- Publication number
- JP2010502210A JP2010502210A JP2009527228A JP2009527228A JP2010502210A JP 2010502210 A JP2010502210 A JP 2010502210A JP 2009527228 A JP2009527228 A JP 2009527228A JP 2009527228 A JP2009527228 A JP 2009527228A JP 2010502210 A JP2010502210 A JP 2010502210A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- slug
- expression
- ovol1
- ovol2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 197
- 201000011510 cancer Diseases 0.000 title claims abstract description 190
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 107
- 230000002068 genetic effect Effects 0.000 title description 2
- 230000014509 gene expression Effects 0.000 claims abstract description 125
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 claims abstract description 124
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 claims abstract description 123
- 238000000034 method Methods 0.000 claims abstract description 102
- 102100026326 Putative transcription factor Ovo-like 1 Human genes 0.000 claims abstract description 95
- 210000004027 cell Anatomy 0.000 claims abstract description 85
- 101001121371 Homo sapiens Putative transcription factor Ovo-like 1 Proteins 0.000 claims abstract description 67
- 101001121409 Homo sapiens Transcription factor Ovo-like 2 Proteins 0.000 claims abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 17
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 13
- 238000003745 diagnosis Methods 0.000 claims abstract description 7
- 102100026385 Transcription factor Ovo-like 2 Human genes 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 101100242392 Homo sapiens OVOL2 gene Proteins 0.000 claims description 29
- 101150012407 OVOL1 gene Proteins 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 21
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 19
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 19
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 238000003757 reverse transcription PCR Methods 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 15
- 238000003384 imaging method Methods 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 12
- 108700008625 Reporter Genes Proteins 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 11
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 238000009739 binding Methods 0.000 claims description 7
- 108700020796 Oncogene Proteins 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 5
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000002853 nucleic acid probe Substances 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000008029 eradication Effects 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 45
- 101150084229 ATXN1 gene Proteins 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 34
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 27
- 108010011042 Envoplakin Proteins 0.000 description 26
- 102100027253 Envoplakin Human genes 0.000 description 26
- 210000005259 peripheral blood Anatomy 0.000 description 22
- 239000011886 peripheral blood Substances 0.000 description 22
- 101150047834 SNAI2 gene Proteins 0.000 description 18
- 239000000090 biomarker Substances 0.000 description 17
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 8
- 229940080856 gleevec Drugs 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 206010055113 Breast cancer metastatic Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229960002411 imatinib Drugs 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- -1 LMOL Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000005296 lung carcinoma Diseases 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 102100023876 Rhombotin-2 Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000005382 thermal cycling Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000003314 affinity selection Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 108010080691 Alcohol O-acetyltransferase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 102100037598 B-cell lymphoma/leukemia 10 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 101150074953 BCL10 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102000006313 Cyclin D3 Human genes 0.000 description 1
- 108010058545 Cyclin D3 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108700037122 EWS-FLI fusion Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102100029234 Histone-lysine N-methyltransferase NSD2 Human genes 0.000 description 1
- 101710196680 Histone-lysine N-methyltransferase NSD2 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101150113681 MALT1 gene Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 description 1
- 102100038732 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Human genes 0.000 description 1
- 101100057962 Mus musculus Atxn1 gene Proteins 0.000 description 1
- 101100455497 Mus musculus Lrig1 gene Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 description 1
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710096632 Rhombotin-2 Proteins 0.000 description 1
- 101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 1
- 101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100023234 Transcription factor MafB Human genes 0.000 description 1
- 108050003944 Transcription factor MafB Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101100042878 Xenopus laevis snai2 gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000017047 asymmetric cell division Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 102000043134 snail C2H2-type zinc-finger protein family Human genes 0.000 description 1
- 108091054456 snail C2H2-type zinc-finger protein family Proteins 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06018771 | 2006-09-07 | ||
| PCT/IB2007/003648 WO2008029290A2 (en) | 2006-09-07 | 2007-09-07 | Identification of cancer stem cells using genetic markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502210A true JP2010502210A (ja) | 2010-01-28 |
| JP2010502210A5 JP2010502210A5 (enExample) | 2010-10-28 |
Family
ID=39157635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527228A Pending JP2010502210A (ja) | 2006-09-07 | 2007-09-07 | 遺伝子マーカーを使用する癌幹細胞の同定 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100034736A1 (enExample) |
| EP (1) | EP2059613A2 (enExample) |
| JP (1) | JP2010502210A (enExample) |
| CA (1) | CA2662843A1 (enExample) |
| WO (1) | WO2008029290A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014521107A (ja) * | 2011-07-21 | 2014-08-25 | ヤンセン・ダイアグノスティックス・エルエルシー | 循環多発性骨髄腫細胞を血液から捕獲及び検出するためのアッセイ |
| KR101805181B1 (ko) | 2016-09-02 | 2017-12-07 | 충북대학교 산학협력단 | 인산화된 slug 단백질의 유사분열 세포에 대한 신규한 바이오 마커로서의 용도 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196905A1 (en) * | 2009-01-30 | 2010-08-05 | Kci Licensing, Inc. | Adult Stem Cell Assays |
| KR101231235B1 (ko) | 2010-04-21 | 2013-02-08 | 고려대학교 산학협력단 | 전립선암 줄기세포 선별용 단백질성 마커 |
| KR101240199B1 (ko) | 2010-04-26 | 2013-03-06 | 고려대학교 산학협력단 | 대장암 줄기세포 선별용 단백질성 마커 |
| CN103151461A (zh) | 2013-02-27 | 2013-06-12 | 京东方科技集团股份有限公司 | 一种有机薄膜晶体管及其制备方法和制备装置 |
| ES2651522T3 (es) * | 2013-12-16 | 2018-01-26 | Humanitas Mirasole S.P.A. | Altos niveles de FT de TEM para el diagnóstico del cáncer, en particular de cáncer colorrectal (CCR) y de páncreas (CP) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2195751B1 (es) * | 2001-11-27 | 2005-04-01 | Universidad De Salamanca (Otri) | Mamiferos no humanos transgenicos como modelos para patologias humanas con origen en celulas stem. |
| CA2469204A1 (en) * | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
| WO2003058201A2 (en) * | 2001-12-31 | 2003-07-17 | Quark Biotech, Inc. | Methods for identifying marker genes for cancer |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| EP1530418A4 (en) * | 2002-05-31 | 2005-10-12 | Univ Leland Stanford Junior | METHOD FOR IDENTIFYING AND INSULATING STEM CELLS AND CANCER STAMPS |
| US20040170605A1 (en) * | 2003-02-27 | 2004-09-02 | Garcia Isidro Sanchez | Use of the slug gene as a genetic marker in functions mediated by SCF (stem cell factor) and applications |
| US7927795B2 (en) * | 2003-06-09 | 2011-04-19 | Board Of Trustees Of The University Of Arkansas | Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| JP2005000056A (ja) * | 2003-06-11 | 2005-01-06 | Sumitomo Pharmaceut Co Ltd | ホルモン依存性癌疾患マーカー及びその利用 |
| WO2006002378A2 (en) * | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| ES2301268B1 (es) * | 2004-10-25 | 2009-05-01 | Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. | Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis. |
| CA2629330C (en) * | 2004-11-12 | 2018-05-22 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
-
2007
- 2007-09-07 EP EP07825743A patent/EP2059613A2/en not_active Withdrawn
- 2007-09-07 CA CA002662843A patent/CA2662843A1/en not_active Abandoned
- 2007-09-07 US US12/440,369 patent/US20100034736A1/en not_active Abandoned
- 2007-09-07 JP JP2009527228A patent/JP2010502210A/ja active Pending
- 2007-09-07 WO PCT/IB2007/003648 patent/WO2008029290A2/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014521107A (ja) * | 2011-07-21 | 2014-08-25 | ヤンセン・ダイアグノスティックス・エルエルシー | 循環多発性骨髄腫細胞を血液から捕獲及び検出するためのアッセイ |
| JP2018100978A (ja) * | 2011-07-21 | 2018-06-28 | ヤンセン・ダイアグノスティックス・エルエルシーＪａｎｓｓｅｎ Ｄｉａｇｎｏｓｔｉｃｓ， ＬＬＣ | 循環多発性骨髄腫細胞を血液から捕獲及び検出するためのアッセイ |
| KR101805181B1 (ko) | 2016-09-02 | 2017-12-07 | 충북대학교 산학협력단 | 인산화된 slug 단백질의 유사분열 세포에 대한 신규한 바이오 마커로서의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100034736A1 (en) | 2010-02-11 |
| EP2059613A2 (en) | 2009-05-20 |
| WO2008029290A2 (en) | 2008-03-13 |
| WO2008029290A3 (en) | 2008-07-17 |
| CA2662843A1 (en) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Psaila et al. | Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets | |
| Martins et al. | Cell competition is a tumour suppressor mechanism in the thymus | |
| Mego et al. | Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy | |
| JP2007516693A (ja) | 癌の治療および診断のための組成物および方法 | |
| Havens et al. | The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis | |
| US20080318234A1 (en) | Compositions and methods for diagnosing and treating cancer | |
| CN105102978A (zh) | 分离循环肿瘤细胞的方法 | |
| JP2008546387A (ja) | 癌を処置および診断するための組成物および方法 | |
| JP2010502210A (ja) | 遺伝子マーカーを使用する癌幹細胞の同定 | |
| US20140322356A1 (en) | Ctc biomarker assay to combat breast cancer brain metastasis | |
| Perez-Lanzon et al. | New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma | |
| WO2009013614A2 (en) | Marker gene | |
| TW202040131A (zh) | 用於純化分離及分析非典型循環腫瘤細胞的方法之應用及非典型循環腫瘤細胞之應用 | |
| US20210088505A1 (en) | Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof | |
| Williamson et al. | Human α2β1HI CD133+ VE epithelial prostate stem cells express low levels of active androgen receptor | |
| Lüke et al. | Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment | |
| US9388469B2 (en) | Sox11 expression in malignant lymphomas | |
| US20150017638A1 (en) | Methods for assessing risk for cancer using biomarkers | |
| Voso et al. | Diagnosis and Classification of AML: WHO 2016 | |
| US7829066B2 (en) | Assay for anti-metastatic agents | |
| JP7521750B2 (ja) | 上皮系マーカー陰性の腫瘍細胞を検出する方法 | |
| US10191055B2 (en) | Detection of acute myeloid leukaemia (AML) leukaemic stem cells (LSC) | |
| US20080311092A1 (en) | Murine Stem Cells and Applications Thereof | |
| Vitek et al. | Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment | |
| US20200209247A1 (en) | Methods for identifying myeloma tumor-initiating cells and targeted therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100906 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20120119 |